Shattuck Labs, Inc. (STTK)
| Market Cap | 473.14M +814.6% |
| Revenue (ttm) | 1,000,000 -78.3% |
| Net Income | -49.87M |
| EPS | -0.59 |
| Shares Out | 75.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 265,321 |
| Open | 6.52 |
| Previous Close | 6.67 |
| Day's Range | 6.22 - 6.60 |
| 52-Week Range | 0.71 - 8.33 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 10.60 (+69.33%) |
| Earnings Date | May 7, 2026 |
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical... [Read more]
Financial Performance
In 2025, Shattuck Labs's revenue was $1.00 million, a decrease of -82.52% compared to the previous year's $5.72 million. Losses were -$48.81 million, -35.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for STTK stock is "Buy." The 12-month stock price target is $10.6, which is an increase of 69.33% from the latest price.
News
Shattuck Labs price target raised to $11 from $8 at Wedbush
Wedbush raised the firm’s price target on Shattuck Labs (STTK) to $11 from $8 and keeps an Outperform rating on the shares. The firm notes the company reiterated guidance for…
Shattuck Labs reports Q1 EPS (13c), consensus (13c)
As of March 31, 2026, cash and cash equivalents and short-term investments were $90.4M, vs. $60.9M as of March 31, 2025. “We are pleased to have completed enrollment in our…
Shattuck Labs sees cash and cash equivalents sufficient into 2029
06:56 EDT Shattuck Labs (STTK) sees cash and cash equivalents sufficient into 2029
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of pote...
Shattuck Labs initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Shattuck Labs (STTK) with an Overweight rating. The stock’s more than 800% rise over the last 12 months reflects enthusiasm for its DR3 and TL1A…
Shattuck Labs price target raised to $18 from $6 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Shattuck Labs (STTK) to $18 from $6 and keeps a Buy rating on the shares. The firm increased its projected SL-325 probability…
Shattuck Labs management to meet with Piper Sandler
Meetings to be held in Boston on April 7, in Greenwich, CT on April 8 and in New York on April 9 hosted by Piper Sandler.
Citi ups Shattuck Labs target, opens ‘upside 90-day catalyst watch’
Citi raised the firm’s price target on Shattuck Labs (STTK) to $7 from $4 and keeps a Neutral rating on the shares. Citi also added an “upside 90-day catalyst watch”…
Shattuck Labs price target raised to $8 from $4 at Wedbush
Wedbush raised the firm’s price target on Shattuck Labs (STTK) to $8 from $4 and keeps an Outperform rating on the shares. The firm notes the company reported earnings, confirmed…
Shattuck Labs transferred with Buy rating at Needham
Needham analyst Joseph Stringer put a Buy rating and $14 price target on Shattuck Labs (STTK) following a transfer of coverage. The firm previously had a Hold rating on the…
Shattuck Labs reports Q4 EPS (12c), consensus (13c)
Reports Q4 revenue $0, consensus $166,670. As of December 31, 2025, cash and cash equivalents and short-term investments were approximately $78.1M, as compared to $73.0M as of December 31, 2024.
Shattuck Labs expects available cash to fund operations into 2029
The company said, “As of December 31, 2025, cash and cash equivalents and short-term investments were approximately $78.1M. Shattuck’s current cash and cash equivalents and short-term investments, inc...
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of po...
Shattuck Labs Transcript: TD Cowen 46th Annual Health Care Conference
A novel DR3 blocking antibody program aims to overcome immunogenicity and efficacy limitations of TL1A blockers in IBD. Phase I data for SL-325 will be released in Q2, with a phase IIb Crohn's trial starting in Q3. Bispecifics and lifecycle management strategies are also advancing.
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-cl...
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targ...
Shattuck Labs initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Shattuck Labs (STTK) with an Overweight rating and $15 price target The company’s SL-325 offers a “differentiated approach” to treat inflammatory bowel disease pati...
Shattuck Labs files $200M mixed securities shelf
16:18 EST Shattuck Labs (STTK) files $200M mixed securities shelf
Shattuck Labs price target raised to $4 from $2 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Shattuck Labs (STTK) to $4 from $2 and keeps a Neutral rating on the shares. The firm sees opportunities in…
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of nove...
Shattuck Labs Transcript: Evercore ISI 8th Annual HealthCONx Conference
Targeting the TL1A receptor may offer superior safety and efficacy over ligand-blocking due to reduced immunogenicity and stable receptor expression. Phase 1 data in healthy volunteers support a differentiated profile, with rapid advancement to phase 2 and combination strategies planned.
Shattuck Labs Transcript: Piper Sandler 37th Annual Healthcare Conference
SL-325, a DR3 blocking antibody, aims to offer more durable and safer inhibition of the TL1A/DR3 axis in inflammatory diseases compared to TL1A blockers. Phase I data will be shared in early 2026, with phase II trials and funding secured through 2029.
Shattuck Labs upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Shattuck Labs (STTK) to Buy from Neutral with a $6 price target The firm cites its bullish stance on the company’s SL-325 program for the upgrade. Shattuck…
Shattuck Labs to Participate in Upcoming December Investor Conferences
AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of nove...
Shattuck Labs reports Q3 EPS (14c), consensus (15c)
“In the third quarter of 2025, SL-325 became the first DR3 blocking antibody to enter clinical development, and our Phase 1 trial is proceeding as we anticipated” said Taylor Schreiber,…